Bcl-2
(Redirected from BCL2)
B-cell Lymphoma 2 (Bcl-2)[edit | edit source]
B-cell lymphoma 2 (Bcl-2), encoded by the BCL2 gene in humans, is a pivotal regulator protein that plays a crucial role in cell death, known as apoptosis. Bcl-2 is the founding member of the Bcl-2 family, a group of regulator proteins that are key players in either inhibiting (anti-apoptotic) or inducing (pro-apoptotic) apoptosis. Discovered as the first apoptosis regulator in any organism, Bcl-2 and its family members have become central to understanding the molecular mechanisms of apoptosis and have significant clinical relevance, particularly in the study and treatment of lymphomas.
Overview[edit | edit source]
The Bcl-2 protein's primary function is to inhibit apoptosis, thereby promoting cell survival. This function is critical in normal physiological processes, such as lymphocyte maturation and the maintenance of a balanced immune response. However, dysregulation of Bcl-2 expression can lead to prolonged cell survival, contributing to the development of cancer, especially lymphoma.
Bcl-2 Family Members[edit | edit source]
The Bcl-2 family consists of both anti-apoptotic and pro-apoptotic proteins, which interact with each other to regulate apoptosis. Key family members include:
- Anti-apoptotic proteins: Bcl-2, Bcl-XL, Mcl-1.
- Pro-apoptotic proteins: Bax, Bak, Bok.
- BH3-only proteins: Bid, Bad, Bim, which act as initiators of apoptosis.
Role in Apoptosis[edit | edit source]
Apoptosis is a form of programmed cell death essential for the removal of damaged or unnecessary cells. The balance between anti-apoptotic and pro-apoptotic Bcl-2 family members determines the cell's fate. Bcl-2, by inhibiting apoptosis, can protect cells from death signals. However, when pro-apoptotic members outweigh the anti-apoptotic ones, apoptosis is induced, leading to cell death.
Clinical Significance in Lymphoma[edit | edit source]
Alterations in the expression of Bcl-2 have been linked to various forms of cancer, most notably lymphoma. The overexpression of Bcl-2, often due to genetic mutations such as the t(14;18) translocation found in many cases of non-Hodgkin lymphoma, leads to excessive inhibition of apoptosis, allowing cancer cells to evade death and proliferate uncontrollably.
Therapeutic Implications[edit | edit source]
The discovery of Bcl-2's role in cancer has led to the development of targeted therapies aimed at inhibiting its function. Bcl-2 inhibitors, such as Venetoclax, have shown promise in treating cancers with high Bcl-2 expression, offering new hope for patients with previously untreatable forms of the disease.
Research and Future Directions[edit | edit source]
Ongoing research is focused on understanding the complex interactions within the Bcl-2 family and developing new therapeutic strategies to modulate apoptosis in cancer treatment. The study of Bcl-2 and its family members continues to provide valuable insights into the mechanisms of cell death and survival, with potential implications across a range of diseases beyond cancer.
External Links[edit | edit source]
Bcl-2 Resources | |
---|---|
|
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen